Edition:
United States

Amgen Inc (AMGN.OQ)

AMGN.OQ on NASDAQ Stock Exchange Global Select Market

190.49USD
20 Jul 2018
Change (% chg)

$-1.27 (-0.66%)
Prev Close
$191.76
Open
$191.48
Day's High
$191.48
Day's Low
$189.49
Volume
1,072,726
Avg. Vol
1,499,239
52-wk High
$201.23
52-wk Low
$163.31

Select another date:

Thu, Jun 28 2018

BRIEF-Amgen And Novartis Present New Data Demonstrating Long-Term Efficacy, Safety And Tolerability Of Aimovig™

* AMGEN AND NOVARTIS PRESENT NEW DATA DEMONSTRATING LONG-TERM EFFICACY, SAFETY AND TOLERABILITY OF AIMOVIG™ (ERENUMAB-AOOE) IN PATIENTS WITH CHRONIC AND EPISODIC MIGRAINE

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases.

Novartis touts effectiveness, safety of autoimmune drug copies

ZURICH, June 15 Novartis on Friday touted safety and efficacy of its biosimilar copies of Johnson & Johnson's Remicade and Amgen Inc's Enbrel, citing a study it hopes will help convince doctors that switching from the original medicines is a viable alternative for treating autoimmune diseases. The Swiss drugmaker said Zessly, its Remicade biosimilar, matched the original medicine for safety and efficacy at 54 weeks, including in patients who switched from the original. Switching from

FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

Mylan NV on Monday beat a clutch of drugmakers racing to get a biosimilar to Amgen Inc's blockbuster drug, Neulasta, to market, with U.S. health regulators approving its version of the infection-fighting treatment.

UPDATE 2-FDA approves Mylan drug as first biosimilar to Amgen's Neulasta

* Mylan shares up 5.2 pct, Amgen down 1.7 pct after market (Adds analyst comment, updates shares)

BRIEF-Amgen Inc Says All Director Nominees Re-Elected To Board

* AMGEN INC - ALL OF DIRECTOR NOMINEES WERE RE-ELECTED TO BOARD AT ANNUAL MEETING OF STOCKHOLDERS

BRIEF-FDA Approves Prolia For Glucocorticoid-Induced Osteoporosis

* FDA APPROVES PROLIA® (DENOSUMAB) FOR GLUCOCORTICOID-INDUCED OSTEOPOROSIS

U.S. FDA approves Amgen drug for prevention of migraines

Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

UPDATE 4-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

CORRECTED-UPDATE 3-U.S. FDA approves Amgen drug for prevention of migraines

May 17 Amgen Inc won U.S. Food and Drug Administration approval on Thursday for the first drug in a new class designed to prevent migraine headaches in adults.

Select another date: